Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteBispecific antibodies engage T cells for antitumor immunotherapy.Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting.Detection of disseminated tumor cells in peripheral blood.Clinical genetics for the pulmonologist: introduction.Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody.Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicityCD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation.Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood.CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alphavbeta3-expressing endothelial cells.Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells.The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies
P2860
Q28066935-A2E7F5DF-48C0-4AA1-B87D-F777FC6AA127Q34174334-9D7B2560-ACED-48C6-B01E-07663B579C35Q34748489-DA547013-F010-47C8-84F3-C7EAD310D11DQ34748723-0C08C479-825C-41D4-87FC-914E1BC9E648Q36115822-2170AA90-C64C-4FFB-BE75-45B004F4DAC7Q36154564-8B946288-3E98-48A3-9D02-1A6BDF0BF91BQ36693320-5BBB6A72-4049-4C2B-9F22-CD75AB79DDD6Q36886598-68B1E0D2-1CC2-479F-A9A1-E0500D016543Q38074885-004862FE-EDB8-45C4-AA29-27F21172C5BCQ39600333-BC6725F2-B183-44F5-8E0A-40FFA0774FFBQ39992093-F08EC03E-160D-4187-9288-BEABF816F9B7Q40423080-0053F506-0FEF-4448-AF2A-3C6EEC6BFB5AQ40963463-C31BEB8E-D44C-41C2-A6CD-CFEEFAB0CBE3Q41833527-CA02AF64-C122-4E41-A299-837A842A0444Q42109422-88EDAD15-8AEC-4806-9912-CE6DE7F760C2Q42590716-CCD408B0-B275-422B-B2F7-3A9EC302784EQ45047687-576C7871-1319-4247-AB32-093BB84D3336Q45865669-2BE5D7AB-1197-468D-94F9-A72724DF729CQ56038596-4F3010D6-68A8-4D1A-90B0-229F2B58C4B6
P2860
Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Phase I study of intravenously ...... ng subcutaneous interleukin 2.
@ast
Phase I study of intravenously ...... ng subcutaneous interleukin 2.
@en
type
label
Phase I study of intravenously ...... ng subcutaneous interleukin 2.
@ast
Phase I study of intravenously ...... ng subcutaneous interleukin 2.
@en
prefLabel
Phase I study of intravenously ...... ng subcutaneous interleukin 2.
@ast
Phase I study of intravenously ...... ng subcutaneous interleukin 2.
@en
P2093
P2860
P356
P1476
Phase I study of intravenously ...... ng subcutaneous interleukin 2.
@en
P2093
Janssen RA
Kroesen BJ
Sleijfer DT
van der Graaf WT
P2860
P2888
P304
P356
10.1038/BJC.1994.366
P407
P577
1994-10-01T00:00:00Z
P5875
P6179
1008339537